Press releases

Year-end report July 1, 2023 – June 30, 2024

30 August, 2024

Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6 million (-1.3) Earnings per share* SEK -0.07 […]


DexTech Medical announces continued positive results from myeloma study

12 August, 2024

The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]


Interim report July 1, 2023 – March 31, 2024

26 April, 2024

Summary of the third quarter (2024-01-01 – 2024-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,5 (-1,6) Earnings per share* SEK -0.08 (-0.08) Summary of […]


DexTech Medical announces new positive results from the myeloma study

15 April, 2024

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]


Half-year report July 1 – December 31, 2023

15 February, 2024

Summary of the second quarter (2023-10-01 – 2023-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,4 (-1,2) Earnings per share* SEK -0,06 (-0.06) * Before […]


DexTech Medical announces positive results from the myeloma study

23 January, 2024

The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX). The baseline value for CTX decreases by […]


DexTech Medical informs about the myeloma study, the first patient is treated

13 December, 2023

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. […]


Bulletin from the Annual General Meeting

31 October, 2023

Today, October 31, 2023, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and […]


Interim report July 1- September 30, 2023

27 October, 2023

Summary of the first quarter (2023-07-01 – 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,1 (-0,8) Earnings per share* SEK -0.05 (-0.04) Cash and […]


DexTech Medical files a new patent application with the European Patent Office

13 October, 2023

Dextech has filed a new patent application regarding GMP production (Good Manufacturing Practice) of the company’s lead candidate OsteoDex with the European Patent Office (EPO.Org). The application describes a GMP […]